Company profile: Philogen
1.1 - Company Overview
Company description
- Provider of biopharmaceuticals targeting angiogenesis and tumor-associated blood vessels for the treatment of cancer and other serious conditions, with a pipeline including Nidlegy (clinical-stage), Fibromun (in clinical development), Darleukin for selective delivery to tumor sites, Dekavil and Dodekin targeting vascular antigens, and Onco IX utilizing vascular targeting.
Products and services
- Darleukin: A drug-candidate designed for selective delivery of therapeutic agents to tumor sites, architected to concentrate treatment precisely within malignant tissues for cancer management
- Fibromun: A biopharmaceutical in clinical-development for cancer and other serious conditions, developed to treat severe pathologies linked to angiogenesis characteristic of these diseases
- NidlegyTM: A clinical-stage product developed for the treatment of cancer, produced to address malignancies where formation of new blood vessels (angiogenesis) is a characteristic feature
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Philogen
Immunic Therapeutics
HQ: United States
Website
- Description: Provider of selective oral immunology therapies, developing: Vidofludimus Calcium (IMU-838), an investigational oral drug for multiple sclerosis and other chronic inflammatory and autoimmune diseases with neuroprotective, anti-inflammatory and anti-viral effects; IMU-856, a Sirtuin 6–targeting small molecule to restore intestinal barrier and regenerate bowel epithelium for gastrointestinal diseases; and IMU-381, a next-generation GI candidate in preclinical testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunic Therapeutics company profile →
EpiBiologics
HQ: United States
Website
- Description: Provider of antibody-based targeted therapies and platforms for tissue-specific degradation of disease-driving membrane and extracellular proteins, including the EpiTAC platform (bispecific antibody system), AbTACs, KineTACs, TrainTAC degrader, and the EpiAtlas platform with a library of over 270 degrader arms.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EpiBiologics company profile →
Upstream Bio
HQ: United States
Website
- Description: Provider of antibody therapies targeting the TSLP receptor, developing verekitug (UPB-101), a monoclonal antibody in Phase 2 trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), and conducting research on Thymic Stromal Lymphopoietin (TSLP) as a driver of inflammatory responses in allergic and inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Upstream Bio company profile →
Gyre Therapeutics
HQ: United States
Website
- Description: Provider of protease therapeutics to address disorders of the coagulation system, operating as a biopharmaceutical company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gyre Therapeutics company profile →
Natrogen Therapeutics
HQ: United States
Website
- Description: Provider of Natura-alpha, a small-molecule oral compound undergoing clinical trials for patients with ulcerative colitis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Natrogen Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Philogen
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Philogen
2.2 - Growth funds investing in similar companies to Philogen
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Philogen
4.2 - Public trading comparable groups for Philogen
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →